Innovation vs. access not the only quandary in cancer drug pricing
By Mari Serebrov
Tuesday, June 10, 2014
Shortages and the high cost of cancer drugs are putting treatment out of reach for many cancer patients in the U.S. In searching for solutions, experts at an Institute of Medicine National Cancer Policy Forum Monday looked at regulatory practices, reimbursement policies and societal attitudes that have contributed to a pricing structure that incentivizes innovation but potentially limits patient access.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.